VRC EBOADC069 00 VP

Drug Profile

VRC EBOADC069 00 VP

Alternative Names: Bivalent Ebola adenoviral vector vaccine - NIAID/Okairos; Bivalent Ebola adenoviral vector vaccine - Okairos/NIAID; Bivalent Ebola vaccine - NIAID/Okairos; Bivalent Ebola vaccine - Okairos/NIAID; Bivalent Ebola virus vaccine - NIAID/Okairos; Bivalent Ebola virus vaccine - Okairos/NIAID; cAd3 EBO - NIAID/Okairos; cAd3-EBO - Okairos/NIAID; chAd-EBOV - NIAID/Okairos; VRC-EBOADC069-00-VP

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Okairos
  • Developer National Institute of Allergy and Infectious Diseases; University of Maryland, Baltimore
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention, In volunteers) in Uganda (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention, In volunteers, In adults) in USA (IM, Injection)
  • 05 Apr 2017 National Institute of Allergy and Infectious Diseases completes a phase I trial for Ebola virus infections (In volunteers, Prevention, In adults) in USA (NCT02231866)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top